CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis

<p>Abstract</p> <p>Background</p> <p>To correlate CD44/CD24 expression with gastric cancer recurrence and prognosis. Gastric cancer is the second leading cause of cancer mortality due to the high recurrence rate, of which the molecular signature has not yet been identif...

Full description

Bibliographic Details
Main Authors: Yong Ching-Shya, Ou Yang Chih-Ming, Chou Yenn-Hwei, Liao Chao-Sheng, Lee Chung-Wei, Lee Chin-Cheng
Format: Article
Language:English
Published: BMC 2012-07-01
Series:BMC Gastroenterology
Subjects:
Online Access:http://www.biomedcentral.com/1471-230X/12/95
_version_ 1818523220557430784
author Yong Ching-Shya
Ou Yang Chih-Ming
Chou Yenn-Hwei
Liao Chao-Sheng
Lee Chung-Wei
Lee Chin-Cheng
author_facet Yong Ching-Shya
Ou Yang Chih-Ming
Chou Yenn-Hwei
Liao Chao-Sheng
Lee Chung-Wei
Lee Chin-Cheng
author_sort Yong Ching-Shya
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>To correlate CD44/CD24 expression with gastric cancer recurrence and prognosis. Gastric cancer is the second leading cause of cancer mortality due to the high recurrence rate, of which the molecular signature has not yet been identified.</p> <p>Methods</p> <p>We retrospectively reviewed the hospital records of patients with gastric cancer. Among 500 patients receiving curative resection, 95 patients had recurrence. Twenty patients from the recurrence group (95 patients) and 20 patients from the non-recurrence group (405 patients) were randomly selected and identified as “study” and “control” groups, respectively. We reviewed patients’ histological study of CD44/CD24 expression by performing immunohistochemistry and recurrence rate.</p> <p>Results</p> <p>Study group had higher TNM stage (III-IV) than control group (80% vs. 25%, <it>P</it> = 0.001). Proportion of lymph node metastasis was significantly higher in study group than that in control group (90% vs. 45%, <it>P</it> = 0.002), and proportion of patients with 5 or more metastatic lymph nodes was also significantly higher in study group than in control group (45% vs. 15%, <it>P</it> = 0.007). Univariate analysis revealed no difference in risk of gastric cancer recurrence between CD44+ and CD44- patients (OR = 1.00, 95% CI: 0.29-3.45, <it>P</it> =1.000). CD24+ patients showed no greater significance of gastric cancer recurrence than CD24- patients (OR = 1.86, 95% CI: 0.52-6.61, <it>P</it> = 0.339). After adjusting for other risk factors, the association of CD44 expression (aOR = 0.66, 95% CI: 0.10-4.26, <it>P</it> = 0.658), CD24 expression (aOR = 0.09, 95% CI: 0.01-1.35, <it>P</it> = 0.081) or combined (CD44/CD24) with gastric cancer recurrence were not significant.</p> <p>Conclusion</p> <p>Neither individual expression of CD24 or CD44, nor combined expression of CD44/CD24 was associated with recurrence of gastric carcinoma.</p>
first_indexed 2024-12-11T05:42:27Z
format Article
id doaj.art-497420deb7504b7599d1461e2a6249e2
institution Directory Open Access Journal
issn 1471-230X
language English
last_indexed 2024-12-11T05:42:27Z
publishDate 2012-07-01
publisher BMC
record_format Article
series BMC Gastroenterology
spelling doaj.art-497420deb7504b7599d1461e2a6249e22022-12-22T01:19:06ZengBMCBMC Gastroenterology1471-230X2012-07-011219510.1186/1471-230X-12-95CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysisYong Ching-ShyaOu Yang Chih-MingChou Yenn-HweiLiao Chao-ShengLee Chung-WeiLee Chin-Cheng<p>Abstract</p> <p>Background</p> <p>To correlate CD44/CD24 expression with gastric cancer recurrence and prognosis. Gastric cancer is the second leading cause of cancer mortality due to the high recurrence rate, of which the molecular signature has not yet been identified.</p> <p>Methods</p> <p>We retrospectively reviewed the hospital records of patients with gastric cancer. Among 500 patients receiving curative resection, 95 patients had recurrence. Twenty patients from the recurrence group (95 patients) and 20 patients from the non-recurrence group (405 patients) were randomly selected and identified as “study” and “control” groups, respectively. We reviewed patients’ histological study of CD44/CD24 expression by performing immunohistochemistry and recurrence rate.</p> <p>Results</p> <p>Study group had higher TNM stage (III-IV) than control group (80% vs. 25%, <it>P</it> = 0.001). Proportion of lymph node metastasis was significantly higher in study group than that in control group (90% vs. 45%, <it>P</it> = 0.002), and proportion of patients with 5 or more metastatic lymph nodes was also significantly higher in study group than in control group (45% vs. 15%, <it>P</it> = 0.007). Univariate analysis revealed no difference in risk of gastric cancer recurrence between CD44+ and CD44- patients (OR = 1.00, 95% CI: 0.29-3.45, <it>P</it> =1.000). CD24+ patients showed no greater significance of gastric cancer recurrence than CD24- patients (OR = 1.86, 95% CI: 0.52-6.61, <it>P</it> = 0.339). After adjusting for other risk factors, the association of CD44 expression (aOR = 0.66, 95% CI: 0.10-4.26, <it>P</it> = 0.658), CD24 expression (aOR = 0.09, 95% CI: 0.01-1.35, <it>P</it> = 0.081) or combined (CD44/CD24) with gastric cancer recurrence were not significant.</p> <p>Conclusion</p> <p>Neither individual expression of CD24 or CD44, nor combined expression of CD44/CD24 was associated with recurrence of gastric carcinoma.</p>http://www.biomedcentral.com/1471-230X/12/95CD44CD24PrognosisRecurrent gastric cancer
spellingShingle Yong Ching-Shya
Ou Yang Chih-Ming
Chou Yenn-Hwei
Liao Chao-Sheng
Lee Chung-Wei
Lee Chin-Cheng
CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
BMC Gastroenterology
CD44
CD24
Prognosis
Recurrent gastric cancer
title CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
title_full CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
title_fullStr CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
title_full_unstemmed CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
title_short CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
title_sort cd44 cd24 expression in recurrent gastric cancer a retrospective analysis
topic CD44
CD24
Prognosis
Recurrent gastric cancer
url http://www.biomedcentral.com/1471-230X/12/95
work_keys_str_mv AT yongchingshya cd44cd24expressioninrecurrentgastriccanceraretrospectiveanalysis
AT ouyangchihming cd44cd24expressioninrecurrentgastriccanceraretrospectiveanalysis
AT chouyennhwei cd44cd24expressioninrecurrentgastriccanceraretrospectiveanalysis
AT liaochaosheng cd44cd24expressioninrecurrentgastriccanceraretrospectiveanalysis
AT leechungwei cd44cd24expressioninrecurrentgastriccanceraretrospectiveanalysis
AT leechincheng cd44cd24expressioninrecurrentgastriccanceraretrospectiveanalysis